Clinical Laboratory Core will provide centralized, quality controlled services for specimen processing and management, clinical and virologic laboratory testing, and study-specific tests. The specific functions of the Core are: I. To process biological samples collected in the clinical studies (Project 1, 2) and from dengue vaccine study subjects (Project 3). Core Laboratory will maintain and manage the sample inventory and sample distribution among collaborating laboratories. II. To perform diagnostic serologic and virologic assays for Projects 1, 2 and 3 a. serological diagnosis of acute dengue virus infections using enzyme immunoassay (EIA) and hemagglutination inhibition assay (HAI). b. measurement of dengue serotype-specific neutralizing antibodies by plaque reduction neutralization assay. c. rapid diagnosis of acute dengue virus infections by qualitative dengue virus RT PCR assay. d. isolation of dengue viruses from plasma samples using Toxorrhynchites splendens mosquitoes. III. To quantify the viral burden. a. measurement of dengue virus RNA levels using a fluorogenic RT PCR assay in plasma/serum samples from acutely infected subjects for Projects 1, 2, and 3. b. measurement of NS1 antigen levels by serotype-specific ELISA in plasma/serum of acutely ill subjects for Project 1, 2, and 3. IV. To perform flow cytometry analyses on fresh blood samples for Projects 1 e.g. detection of activated T cells and functional characterization of dengue-specific T and B cells during an acute infection.
The proposed program project represents integrated research activities addressing several important aspects of dengue. The study will be conducted at multiple study sites and laboratories. To support such integrated and complex research activities a Clinical Laboratory Core which will provide centralized, quality controlled services for specimen processing and management and routine clinical and virologic laboratory testing is needed.
| Park, Sangshin; Srikiatkhachorn, Anon; Kalayanarooj, Siripen et al. (2018) Use of structural equation models to predict dengue illness phenotype. PLoS Negl Trop Dis 12:e0006799 |
| Salje, Henrik; Cummings, Derek A T; Rodriguez-Barraquer, Isabel et al. (2018) Reconstruction of antibody dynamics and infection histories to evaluate dengue risk. Nature 557:719-723 |
| Srikiatkhachorn, Anon; Mathew, Anuja; Rothman, Alan L (2017) Immune-mediated cytokine storm and its role in severe dengue. Semin Immunopathol 39:563-574 |
| Rattanamahaphoom, Jittraporn; Leaungwutiwong, Pornsawan; Limkittikul, Kriengsak et al. (2017) Activation of dengue virus-specific T cells modulates vascular endothelial growth factor receptor 2 expression. Asian Pac J Allergy Immunol 35:171-178 |
| Kalayanarooj, Siripen; Rothman, Alan L; Srikiatkhachorn, Anon (2017) Case Management of Dengue: Lessons Learned. J Infect Dis 215:S79-S88 |
| Kang, Jeon-Young; Aldstadt, Jared (2017) The Influence of Spatial Configuration of Residential Area and Vector Populations on Dengue Incidence Patterns in an Individual-Level Transmission Model. Int J Environ Res Public Health 14: |
| Moulton, Steven L; Mulligan, Jane; Srikiatkhachorn, Anon et al. (2016) State-of-the-art monitoring in treatment of dengue shock syndrome: a case series. J Med Case Rep 10:233 |
| Srikiatkhachorn, Anon; Yoon, In-Kyu (2016) Immune correlates for dengue vaccine development. Expert Rev Vaccines 15:455-65 |
| Rothman, Alan L; Ennis, Francis A (2016) Dengue Vaccine: The Need, the Challenges, and Progress. J Infect Dis 214:825-7 |
| Townsley, E; O'Connor, G; Cosgrove, C et al. (2016) Interaction of a dengue virus NS1-derived peptide with the inhibitory receptor KIR3DL1 on natural killer cells. Clin Exp Immunol 183:419-30 |
Showing the most recent 10 out of 119 publications
